<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629224</url>
  </required_header>
  <id_info>
    <org_study_id>8825-CL-0012</org_study_id>
    <nct_id>NCT02629224</nct_id>
  </id_info>
  <brief_title>ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis</brief_title>
  <official_title>Pharmacokinetic (PK) Study of ASP8825 - Evaluation of Pharmacokinetics in Patients With Impaired Renal Function and Haemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the pharmacokinetics and safety of ASP8825 in
      patients with impaired renal function and haemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) parameter of gabapentin in plasma: Cmax in Renal impairment patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48 and 72 hr after dosing</time_frame>
    <description>Cmax: Maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in plasma: tmax in Renal impairment patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48 and 72 hr after dosing</time_frame>
    <description>tmax: Time of Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of gabapentin in plasma: AUC24h in Renal impairment patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48 and 72 hr after dosing</time_frame>
    <description>AUC24h: Area under the concentration-time curve from the time of dosing to 24hours after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of gabapentin in plasma: Cmax in Haemodialysis patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 25, 26, 27, 28, 30, 36 and 48 hr after dosing</time_frame>
    <description>Cmax: Maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in plasma: tmax in Haemodialysis patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 25, 26, 27, 28, 30, 36 and 48 hr after dosing</time_frame>
    <description>tmax: Time of Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of gabapentin in plasma: AUC24h in Haemodialysis patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 25, 26, 27, 28, 30, 36 and 48 hr after dosing</time_frame>
    <description>AUC24h: Area under the concentration-time curve from the time of dosing to 24hours after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in plasma: AUClast in Renal impairment patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48 and 72 hr after dosing</time_frame>
    <description>AUClast: Area under the concentration-time curve from the time of dosing to the last measurable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of gabapentin in plasma: AUCinf in Renal impairment patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48 and 72 hr after dosing</time_frame>
    <description>AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in plasma: kel in Renal impairment patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48 and 72 hr after dosing</time_frame>
    <description>kel: Elimination rate constant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in plasma: t1/2 in Renal impairment patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48 and 72 hr after dosing</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in plasma: CL/F in Renal impairment patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48 and 72 hr after dosing</time_frame>
    <description>CL/F: Apparent total systemic clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in plasma: Vz/F in Renal impairment patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48 and 72 hr after dosing</time_frame>
    <description>Vz/F: Apparent volume of distribution during the terminal elimination phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in plasma: MRTinf in Renal impairment patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48 and 72 hr after dosing</time_frame>
    <description>MRTinf: Mean residence time from the time of dosing extrapolated to time infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in plasma: t1/2, pre in Haemodialysis patients</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 18 hr after dosing</time_frame>
    <description>t1/2, pre: Elimination half-life for pre-hemodialysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in plasma: t1/2, HD in Haemodialysis patients</measure>
    <time_frame>24, 25, 26, 27 and 28 hr after dosing</time_frame>
    <description>t1/2,HD: Elimination half-life for hemodialysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in plasma: t1/2, post in Haemodialysis patients</measure>
    <time_frame>30, 36 and 48 hr after dosing</time_frame>
    <description>t1/2, post: Elimination half-life for post-hemodialysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin: CLDP in Haemodialysis patients</measure>
    <time_frame>25, 26, 27 and 28 hr after dosing</time_frame>
    <description>CLDP: Hemodialysis clearance calculated from the concentration of gabapentin at pre-dialyzer and post-dialyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in plasma: AUCD in Haemodialysis patients</measure>
    <time_frame>24, 25, 26, 27 and 28 hr after dosing</time_frame>
    <description>AUCD: Area under the concentration-time curve from the start to end of haemodialysis the concentration of gabapentin in plasma pre-dialyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in urine: Ae72h in Renal impairment patients</measure>
    <time_frame>Up to 72 hr after dosing</time_frame>
    <description>Ae72h: Amount of gabapentin excreted into the urine from the time of dosing to 72 hr after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in urine: Ae%72h in Renal impairment patients</measure>
    <time_frame>Up to 72 hr after dosing</time_frame>
    <description>Ae%72h: Percent of gabapentin excreted into the urine from the time of dosing to 72 hr after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in urine: CLR in Renal impairment patients</measure>
    <time_frame>Up to 72 hr after dosing</time_frame>
    <description>CLR: Renal clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in urine: Ae48h in Haemodialysis patients</measure>
    <time_frame>Up to 48 hr after dosing</time_frame>
    <description>Ae48h: Amount of gabapentin excreted into the urine from the time of dosing to 48 hr after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in urine: Ae%48h in Haemodialysis patients</measure>
    <time_frame>Up to 48 hr after dosing</time_frame>
    <description>Ae%48h: Percent of gabapentin excreted into the urine from the time of dosing to 48 hr after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in dialyzing fluid: Adt in Haemodialysis patients</measure>
    <time_frame>Up to 48 hr after dosing</time_frame>
    <description>Adt: Cumulative amount in dialyzing fluid from the time of dosing to time after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in dialyzing fluid: Adt% in Haemodialysis patients</measure>
    <time_frame>Up to 48 hr after dosing</time_frame>
    <description>Adt%: Excretion rate in dialyzing fluid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin in dialyzing fluid: CLDD in Haemodialysis patients</measure>
    <time_frame>Up to 48 hr after dosing</time_frame>
    <description>CLDD: Hemodialysis clearance calculated from the Cumulative amount in dialyzing fluid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by AEs</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
    <description>AEs: Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Vital signs</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
    <description>Supine blood pressure, supine pulse rate and axillary body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Laboratory tests</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
    <description>Hematology, blood biochemistry, and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by 12-lead ECGs</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
    <description>ECG: Electrocardiogram</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Patients With Impaired Renal Function and Haemodialysis</condition>
  <arm_group>
    <arm_group_label>Renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Haemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP8825</intervention_name>
    <description>Oral</description>
    <arm_group_label>Renal impairment</arm_group_label>
    <arm_group_label>Haemodialysis</arm_group_label>
    <other_name>gabapentin enacarbil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight: ≥40.0 kg and &lt;80.0 kg

          -  Body mass index BMI: ≥16.0 and &lt;30.0 [BMI= Body weight (kg)/(Height (m))2]

          -  For Renal impairment patients: Patients with eGFR by GFR predictive equation for
             Japanese within &lt; 50 mL.min/1.73m2 at screening and who is not undergoing dialysis

          -  For Haemodialysis patients: Patients who receive dialysis at screening

          -  Patients whose treatment regimen (including diet) for renal impairment or
             complications remain unchanged within 14 days prior to dosing, or patients who receive
             treatments (including diet) that need not to be changed during the period from 14 days
             before dosing to follow-up examination in the opinion of the investigator or
             sub-investigator.

          -  Female subjects who agree use effective contraception starting at informed consent and
             throughout the study period

        Exclusion Criteria:

          -  Patients with a complication or history of the inappropriate for this study (except
             for a complication of primary disease for renal dysfunction, like diabetes etc., or
             complication of hypertension or anemia etc.)

          -  Patients with a complication or history of recurring alimentary disease

          -  Patients with a history of gastrointestinal surgical operation

          -  Patients with a complication of severe heart disease

          -  Patients with a complication or history of malignant tumor (However, a patient without
             recurrence of the malignant tumor for more than 5 years after the treatment may be
             eligible for the study.)

          -  Patients judged ineligible by the investigator or sub-investigator based on the
             results of medical examination, vital sign, 12-ECG and laboratory test

          -  Patients who have an Hb value &lt;9g/dL at screening

          -  Patients who received or are scheduled to receive any study drugs in other clinical
             trials or post-marketing studies within 120 days before screening

          -  Patients who received or are scheduled to receive medications within seven days before
             the dosing of the investigational drug

          -  Patients who previously received administration of Gabapentin or ASP8825
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=8825-CL-0012</url>
    <description>Link to results on Astellas Clinical Study Results Web site</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impaired renal function</keyword>
  <keyword>Haemodialysis</keyword>
  <keyword>ASP8825</keyword>
  <keyword>XP13512</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

